In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...

IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...

Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...

Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...

MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...

DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.90 per share a year ago. These ...

IGM Financial Price Performance Shares of IGM opened at C$42.85 on Thursday. The company has a debt-to-equity ratio of 35.99, a current ratio of 2.12 and a quick ratio of 0.31. The company’s ...

What is the current share price of Rhythm Biosciences Limited (RHY)? Rhythm Biosciences Limited's (RHY) current share price is $0.10. This constitutes a price movement of 9.09% when compared to the ...

Amgen (AMGN) came out with quarterly earnings of $5.58 per share, beating the Zacks Consensus Estimate of $5.11 per share. This compares to earnings of $4.96 per share a year ago. These figures are ...

Colossal Biosciences’ four-part ‘Tassie the tiger’ series hits screens today, exploring the thylacine, its importance to Tasmania and how de-extinction could work. Tasmanian Thylacine Advisory ...